Signatera blood test in early-stage endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is testing a blood test called Signatera to see if it can find leftover cancer DNA after treatment for early-stage endometrial cancer. It may help doctors decide who needs more treatment and who can safely be watched.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have had surgery (hysterectomy) and lymph node assessment for your endometrial cancer.
- Your cancer is early stage (Stage I or II) and has certain high-risk features or a specific type (like serous, clear cell, or endometrioid with certain risk factors).
- You have not had any prior treatment for endometrial cancer (like chemotherapy, radiation, or hormone therapy).
- You have not had another cancer in the last 5 years (except for non-melanoma skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
This study is testing whether a special kind of medicine called a PARP inhibitor can work against endometrial cancer cells grown in a lab from your tumor. The goal is to find out which patients might benefit from this treatment in the future.
This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.
This study looks at combining genetic testing with surgical exams to better understand endometrial cancer. It may help doctors see which treatments could work best for you.
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
This study tests whether a simple blood test (called ctDNA) can help decide if you need additional chemotherapy after surgery for stomach or esophageal cancer. The goal is to avoid unnecessary treatment for patients who are already cancer-free while ensuring those who need it get the right therapy.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.